Product hopping may take on a new meaning with the advent of Medicare price negotiation. Instead of being deployed by innovator companies to effectively maintain a monopoly when a drug is facing generic or biosimilar competition, product hopping could be combined with some type of managed competition as a way to avoid government price controls.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?